Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with ...

Software that uses artificial intelligence to analyze medical imaging tests may help facilitate earlier diagnosis and more accurate monitoring of pulmonary fibrosis in people with underlying lung ...

Columnist Sam Kirton explains when the new FDA-approved IPF treatment Jascayd might be made available to patients.

Guest writer Kylene Henderson recalls the lengthy journey she and her husband faced to get answers and a pulmonary fibrosis diagnosis.

Pulmonary fibrosis (PF) is a respiratory disease characterized by fibrosis, or tissue scarring, in the lungs. To function normally, lungs need to be stretchy and elastic like a balloon in order to ...

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

Besides medication that can help manage symptoms and slow the progression of pulmonary fibrosis (PF), there are other therapeutic strategies available that can help patients cope with the effects of ...

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Enrollment has been completed for a Phase 2b trial that’s testing LYT-100 (deupirfenidone), PureTech Health’s experimental therapy for idiopathic pulmonary fibrosis (IPF). The trial, called ELEVATE ...